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Abstract
Stiff person syndrome (SPS) is a rare, neurological disorder characterized by sudden cramps and spasms. High titers of
enzyme-inhibiting IgG autoantibodies against the 65 kD isoform of glutamic acid decarboxylase (GAD65) are a hallmark of
SPS, implicating an autoimmune component in the pathology of the syndrome. Studying the B cell compartment and the
anti-GAD65 B cell response in two monozygotic twins suffering from SPS, who were treated with the B cell-depleting
monoclonal anti-CD20 antibody rituximab, we found that the humoral autoimmune response in SPS is composed of a
rituximab-sensitive part that is rapidly cleared after treatment, and a rituximab-resistant component, which persists and acts
as a reservoir for autoantibodies inhibiting GAD65 enzyme activity. Our data show that these potentially pathogenic anti-
GAD65 autoantibodies are secreted by long-lived plasma cells, which may either be persistent or develop from rituximab-
resistant memory B lymphocytes. Both subsets represent only a fraction of anti-GAD65 autoantibody secreting cells.
Therefore, the identification and targeting of this compartment is a key factor for successful treatment planning of SPS and
of similar autoimmune diseases.
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Introduction
Serum antibodies are secreted by plasma cells, which originate
in germinal centers from activated B cells that have been selected
for high-affinity binding to antigen. A subset of the plasma cells
will become long-lived [1,2,3], forming the humoral memory of
the human immune system, which may persist over decades [4].
Since plasma cells do not express the B cell surface marker
CD20 they are not removed by treatment with monoclonal
antibodies like rituximab, which is depleting all CD20
+ B cells
through mechanisms including antibody-dependent cellular cyto-
toxicity, complement-dependent cytotoxicity, and apoptosis [5].
Since it has been proposed that a substantial fraction of antibodies
against microbial antigens like pneumococcal polysaccharides or
tetanus toxoid (TT) [6] is secreted by long-lived plasma cells,
rituximab-mediated B cell depletion has little effects on the long-
term humoral memory against these antigens [6,7]. Varying
results have been reported for rituximab treatment of autoimmune
diseases. For example in pemphigus, anti-CD20 treatment strongly
reduces anti-desmoglein titers and causes disease remission by
preventing the development of short-lived plasma cells from B cells
at the inflamed sites[8], whereas anti-CD20 treatment of patients
with Graves’ disease does not cause sustained reduction of anti-
TSH receptor autoantibodies [9].
Stiff Person Syndrome (SPS) is a rare neurologic disease with a
strong autoimmune component. It has an incidence of ,1/1
million and is characterized by progressive and fluctuating tonic
muscle contractions, muscle stiffness, sudden spasms of the
proximal musculature and continuous, because uninhibited, motor
neuron activity [10,11]. The muscle spasms result from an
imbalance of the signals generated by excitatory and inhibitory
neuronal circuits that regulate motor neuron activity.
In the nervous system, inhibitory signals are transmitted by c-
amino butyric acid (GABA) [12], which is synthesized by the
enzyme glutamic acid decarboxylase (GAD), catalyzing the
decarboxylation of its substrate, glutamate, the most abundant
excitatory neurotransmitter. In humans, the two GAD isoforms
are encoded by the GAD1 (GAD67) and GAD2 (GAD65) genes
[13,14]. More than 65% of SPS patients present with very high
titers of autoantibodies directed against the 65 kD isoform of
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postulated since they can inhibit the enzymatic activity of GAD65
in vitro [15,16]. Indeed, GABA levels are diminished in the brain
and cerebrospinal fluid of SPS patients [17,18]. Moreover, in SPS
patients plasmapheresis or intravenous immunoglobulins treat-
ments have beneficial effects, suggesting that removal or
neutralization of anti-GAD65 antibodies ameliorates SPS [19,20].
We investigated the contribution of memory B cells and long-
lived plasma cells to SPS, by analyzing changes in antibody titers
and specificities, frequency and repertoire of specific memory cell
before and after rituximab treatment in a pair of monozygotic
twins suffering from SPS [21]. The anti-CD20
+ treatment
efficiently removed all circulating B cells, changed the B cell
repertoire, the specificities of autoantibodies binding to linear
GAD65 epitopes and to inhibitory synapses in the brain, and
resolved in a relative increase in GAD65 specific memory cells.
However, the levels of enzyme-inhibiting anti-GAD65 autoanti-
bodies, their binding to conformational GAD65 epitopes, and the
clinical course in both patients remained unchanged. Therefore,
autoantibodies in SPS can be divided in two fractions, one
sensitive and one resistant to rituximab treatment. The latter are
produced either by long-lived plasmacells or by activated memory
cells resistant to rituximab treatment. If rituximab-resistant cells
contribute to the pathology of SPS, targeting those cells could
improve the treatment of SPS.
Results
A portion of anti-GAD65 antibodies, including GAD65
inhibiting antibodies, persists after anti-CD20 treatment
Two monozygotic twins affected by SPS were treated with 2
single 1000 mg injections of rituximab at 2 weeks of interval,
however during 1 year of follow-up clinical improvements were
not observed [21]. Before receiving rituximab-treatment, both
patients had an elevated percentage of circulating B cells (22% and
21% CD19
+ cells in twin A and B, respectively, normal range 5–
18%) with a normal distribution of naı ¨ve and memory B cells as
well as plasmablasts (Table 1). Eight and 18 weeks after rituximab
treatment, CD19
+ B cells were undetectable in peripheral blood.
In line with previously published data [22,23], the B cell
compartment in peripheral blood was partially regenerated 36
weeks after rituximab and returned to pre-treatment values at
week 54, however with a predominance of naı ¨ve and transitional B
cell subsets (.95% and .8% respectively). The percentages of
class switched memory and marginal zone B cells were both
reduced 4 to 5-fold compared to pre-treatment values, whereas the
proportion of plasmablasts increased from 1.06% to 1.72% in twin
A and from 0.5% to 1% in twin B (Table 1). During the entire
monitoring period the total serum IgG concentration remained
constant [21]. Twin A and twin B had initially very high anti-
GAD65 antibody serum titers (1/256,000), exceeding the titers of
control sera by 10,000-fold (average 1/40, range: not detectable to
1/80; n=8). Despite the fact that a 2-fold decline in anti-GAD65
antibody titer to 1/128,000 was observed in both patients 8 weeks
after anti-CD20 treatment and persisted up to week 36, the titers
remained at least 2,000-fold above the controls (Fig. 1A). These
data indicate that only about half of anti-GAD65 antibodies are
sensitive to anti-CD20 mediated B cell depletion. Similar to the
anti-GAD65 serum titers the IgG concentrations of antibodies
specific for TT, rotavirus group A antigen and S. pneumoniae cell
wall (PnPs) antigens either remained unchanged or increased upon
rituximab treatment (Fig. 1 C–F).
Anti-GAD65 antibodies are also detected in other autoimmune
diseases [24,25,26,27], but only those ones present in SPS are
known to inhibit GAD65 enzyme activity in vitro. Therefore we
analyzed the enzyme-inhibiting activity of IgG isolated from both
twins. Before rituximab therapy, half-maximal inhibition of
GAD65 enzyme activity (IC50) was reached at 1.1 mg/ml IgG
for twin A, and 0.65 mg/ml IgG for twin B (Fig. 1B). After
rituximab treatment the concentration of half maximal inhibition
of GAD65 enzyme activity remained almost unchanged with
1.3 mg/ml for twin A, and 0.95 mg/ml for twin B. These data
indicate that anti-GAD65 antibodies with enzyme inhibiting
activity were not affected by rituximab treatment.
Persistence of GAD65-specific memory B cells after
anti-CD20 mediated B cell depletion
It has been postulated that polyclonal activation of circulating,
antigen specific memory B cells may account for the continuous
generation of plasma cells and for the maintenance of humoral
memory [28]. We therefore analyzed if the frequency of GAD65-
specific memory B cells remained constant after anti-CD20
treatment. Peripheral blood mononuclear cells (PBMC) from
three healthy donors and twin A were stimulated polyclonally in
limiting dilution assays, and IgG production specific for GAD65
and TT was tested by ELISA. Before anti-CD20 therapy, 184
IgG
+ GAD65-specific cells per 10
6 IgG
+ memory B cells were
found in twin A, a frequency that was almost identical to that in
healthy controls (183642 GAD65-specific IgG
+ per 10
6 IgG
+
memory B cells). This finding is not surprising as recently
published data show that for certain antigens, the frequency of
memory B cells does not correlate with antibody titers [29]. A
relative 4-fold increase (699/10
6) in the frequency of GAD65
Table 1. B cell subpopulations distribution in response to rituximab treatment.
CD19%
Naive IgM
+
IgD
+%
Memory
CD27
+IgD%
2
Transitio-nal IgM
++
CD38
+ CD24
+%
Plasma-blasts
CD27
+ CD38
++%
MZ cells CD27
+
IgD
+ IgM
+%
HD 4.7–18.20 67.3–91.8 6.5–29.2 0.6–3.5 0.4–3.6 7.8–36
week 0 22 88.97 10.17 4.5 1.06 11.8
Twin A week 8 0 n.d. n.d. n.d. n.d. n.d.
week 36 7 97.91 1.85 23.26 1.72 2.5
week 0 21.2 89.4 9.2 2.6 0.5 8.9
Twin B week 18 0 n.d. n.d. n.d. n.d. n.d.
week 54 22.6 96.7 2.9 9.4 1 2.1
n.d.: not done.
doi:10.1371/journal.pone.0010838.t001
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treatment (Fig. 2A). A relative 4-fold increase was also observed in
memory B cells specific for TT (120/10
6 before and 513/10
6 after
anti-CD20, Fig. 2B).
BCR repertoire analysis reveals a clonal expansion of
switched memory cells after anti-CD20 mediated B cell
depletion
Since changes in the frequency of memory B cells may reflect a
change in the B cell repertoire, we analyzed the heavy chain
variable regions (VH) of IgM, IgG and IgA in both twins by
spectratyping [30]. The VH3a, VH3b, and VH4 families were
most frequently used by all immunoglobulin isotype heavy chains
before and after rituximab treatment (Fig. 3A). Similar VH usage
was also reported previously for healthy subjects [30].
The diversity of the B cell repertoire is reflected by the highly
variable length of the complementarity determining regions 3
(CDR3) of immunoglobulin H-chains, encoded by the region
spanning the VDJ rearrangement. Representative examples for
the CDR3 length distribution of the major VH families VH3a,
VH3b and VH4 are shown by the immunoscope profiles in
figure 3B. Before anti-CD20 treatment, both patients had a
polyclonal IgM B cell repertoire, reflected by the Gaussian
distribution of the CDR3 length, with an expanded CDR3 peak in
VH3a in twin B. The skewed distribution of IgG and IgA CDR3,
Figure 1. A portion of antibodies in SPS patients is not influenced by rituximab treatment. Rituximab treatment induces a 2-fold
decrease of GAD65 specific serum antibody titer. (A) Serum samples from twin A and twin B were collected before and 8, 16, 36 weeks after rituximab
treatment, and GAD65 specific antibody titers were measured by ELISA. The titers of 8 healthy donors ranged between undetectable and 1/80. (B)
Inhibition of GAD65 enzyme activity was tested with IgG of twin A and twin B isolated at week 0 and 36 after starting the anti-CD20 treatment. (C,D)
TT and Rotavirus antibody titers. Serum from twin A and twin B was collected at week 0 and 36 post rituximab treatment, and antibody titer was
measured by ELISA. Eight healthy donors (HD) were used as controls. (E, F) Pneumococcal polysaccharide (PnP) antigens antibody titers in twin A (E)
and in twin B serum (F), at week 0 and 36 post treatment, x axes show the different PnP antigens tested.
doi:10.1371/journal.pone.0010838.g001
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detected in both patients. In addition, both twins had expanded
IgG
+ B cell clones using VH3a, VH3b and VH4, which were
represented by dominant CDR3 regions of 9, 8, 12, and 14 amino
acids length. For twin A, these peaks were also detected in the
corresponding IgA profiles. After rituximab treatment the
polyclonal repertoire of the newly formed IgM
+ B cells showed
new expansion peaks in the VH3a, VH3b, and VH4 families
(Fig. 3B). The switched memory repertoire of VH3a, 3b and VH4
expressing IgG
+ and IgA
+ B cells was again oligoclonal and
contained expanded new B cell clones with CDR3 length different
from the ones present before anti-CD20 treatment.
Analysis of epitope-specificity reveals different
sensitivities to rituximab treatment
IgG autoantibodies directed against GAD65 are found in 60–
80% of newly diagnosed type 1 diabetes patients, in other
neurological diseases [24,25,26,27], and also in about 1% of the
general population [32]. Remarkably, the epitope specificity of the
anti-GAD65 antibodies is characteristic for the different diseases
[33]. Since rituximab treatment influenced the anti-GAD65
antibody titer and the clonal expansion of switched memory B
cells, we searched for changes in the epitope specificity of the
humoral repertoire.
Using recombinant Fab (rFab) fragments derived from GAD65-
specific monoclonal antibodies that bind to different conforma-
tional epitopes and parts of the protein [34], we performed
competitive GAD65 binding assays. Binding of IgG isolated from
both patients to GAD65 before therapy was strongly inhibited by
rFabs b78 and b96.11 (Fig. 4 A,B). GAD65 specific antibodies that
recognize the same epitope as b78 significantly inhibit GAD65
activity in vitro and are primarily detected in SPS patients [35].
Anti-CD20 treatment did neither change the binding pattern of
patients IgG to the GAD65 epitopes recognized by b96.1 and b78
(Fig. 4A and B), nor its enzyme inhibiting activity (Fig. 1B).
Since we found that autoantibodies to conformational epitopes of
GAD65 were still present after rituximab treatment, we also
compared the specificities against linear epitopes before and after
rituximab therapy and analyzed binding of serum IgG from both
patients to 96 overlapping linear 15-mer peptides spanning the
entire GAD65 amino acid sequence. The peptide array analysis
revealed five peptides located within the first 99 amino acid residues
of GAD65, which were recognized by the IgG of both patients
before rituximab treatment was initiated (Fig. 5 A–C and Fig. S1).
In addition, a peptide spanning residues 14–28 was detected by IgG
from twin A but not from twin B (Fig. S1). Anti-CD20 treatment
changed the binding of IgG of twin A to 5 peptides spanning
residues 1–15, 37–57, and 79–99, whereas the peptide recognition
pattern of twin B remained constant (Fig. 5 A–C). Lower IgG titers
for these 5 peptides were found already 8 weeks after rituximab
treatment and progressively decreased later on (Fig. 5 D–H). Since
the half-life of IgG is 3–5 weeks [36], these data indicate that the B
cells producing these specificities are eliminated by treatment and
the antibodies are progressively diluted in the serum.
Since memory B cells could be precursors for plasma cells
secreting IgG binding to linear GAD65 epitopes, we characterized
the specificity of IgG expressed by memory B cells for linear
peptides. Comparing supernatants of GAD65 specific memory B
cell clones from twin A and from one healthy donor we found
similar specificities in both sets of samples with the exception of a
few peptides (Fig. S2, black and blue arrows).
Antibodies recognizing brain structures are sensitive to
anti-CD20 treatment
Severe muscular spasms caused by dysfunction of inhibitory
neurons are the cardinal symptoms of SPS, therefore we analyzed
whether the patients’ IgG would bind to GAD65 containing
inhibitory synapses. Cerebellar sections from mice and human
control samples were stained with IgG isolated from both patients,
from control subjects and, as a reference, with antibodies specific
for GAD65 and calbindin, a protein highly enriched in cerebellar
Purkinje cells (Fig. 6). Specific binding of patient IgG to GAD65
+
GABAergic pre-synaptic terminals of calbindin
+ cells was detected
in the Purkinjie cell layer of both mouse and human cerebellum as
shown in figure 6 for twin B. After rituximab treatment less
GAD65
+ synapses were stained (Fig. 6A, row b and d). Control
IgG isolated from healthy donors only stained nuclei but not the
synaptic structures defined by the GAD65-specific reference
antibody (Fig. S3 row a and c). The differences in staining
patterns and intensities were quantified by 360 independent
intensity measurements, corresponding to a 7.2 mm long-scan
encompassing GAD65
+ synapses of mouse cortex, cerebellum and
pons (Fig. 6B). Since the staining intensities only reached
background levels after rituximab treatment, the experiments
strongly suggest that the autoantibodies binding pre-synaptic
structures were produced by plasma cells originating from
rituximab sensitive precursors cells.
Discussion
Impaired function of interneurons and high titers of anti-
GAD65 autoantibodies capable of inhibiting GAD65 enzyme
Figure 2. Relative increase in frequency of specific memory B cells after rituximab treatment. Frequency of IgG
+ memory cells specific for
GAD65 (A) and TT (B) was analyzed by limiting dilution assays at week 0 and 36 for twin A, and for three healthy donors (HD).
doi:10.1371/journal.pone.0010838.g002
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PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10838Figure 3. Constant VH usage, but changes in CDR3 length distribution in SPS patients after rituximab treatment. (A) The mean
frequency of VH usage for each isotype was determined by quantitative real time PCR analysis on B cells from patients at week 0 and at week 36. As
control VH usage by B cells from a healthy donor (HD) is shown. (B) CDR3 length distribution in IgM
+, IgG
+ and IgA
+ B cell of twin A and B before and
after rituximab treatment was analyzed by spectratyping[30]. The x axis of spectratype indicates CDR3 length, whereas the y axis represents the
frequency of CDR3 regions. The percentage of VH utilization among all three isotypes is indicated on each profile. Arrows indicate overrepresented
CDR3 regions.
doi:10.1371/journal.pone.0010838.g003
Humoral Memory in SPS
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been treated successfully by plasmapheresis [19,37] and intrave-
nous IgG[20,38], which has been shown to result in a significant
decline in anti-GAD65 antibodies. Analyzing the anti-GAD65
antibody titer and specificity in two monozygotic twins receiving
rituximab treatment [21], we found that the humoral autoanti-
body repertoire in SPS is composed of two fractions. The first
fraction contains autoantibodies against linear GAD65 epitopes
and brain structures. It is produced by plasma cells that originate
from rituximab sensitive precursors. The second fraction of anti-
GAD65 antibodies binds to conformational epitopes, has enzyme
inhibiting activity, and is produced by plasma cells which are not
targeted by rituximab treatment. While anti-CD20 treatment
eliminated all circulating B cells, it had little effect on the serum
concentrations of anti-GAD65 IgG, the enzyme-inhibiting activity
of anti-GAD65 IgG from both patients, or the recognition of
conformational epitopes. Since anti-CD20 mediated B cell
depletion did not improve the clinical manifestations of the
syndrome it is conceivable that these anti-GAD65 antibodies play
a role in the pathogenesis of the disease. Moreover, additional
autoantibodies with similar characteristics may also contribute to
SPS. Comparing the antibody repertoires between both twins we
observed identical recognition patterns of conformational and
linear epitopes before B cell depletion. However, after rituximab
treatment, binding to linear GAD65 epitopes was much weaker for
IgG isolated from twin A that from twin B showing that the
humoral autoimmune response against GAD65 is not entirely
dependent on genetic factors.
Since the half-life of circulating IgG antibodies is about 3–5
weeks [36], constant IgG titers are most likely maintained by the
continuous secretion of antibodies by plasma cells. Studies of B cell
populations and autoantibodies, such as rheumatoid factor and
anti-citrunillated peptide antibodies in rheumatoid arthritis
patients who had been treated with rituximab, have reported an
almost complete elimination of B cells from blood and a significant
drop in autoantibody titers [23,39]. In contrast, the reduction of
class-switched memory B cells and plasma cells in the rheumatoid
synovium and in the bone marrow was observed only in some but
not all rheumatoid arthritis patients [39,40,41,42]. This implicates
that not only autoantibody producing plasma cells, but also
autoreactive switched memory B cells, which serve as plasma cell
precursors, can survive anti-CD20 treatment at least in some
tissues. Since we found a relative increase in anti-GAD65 IgG
+
memory B cells in the recovering blood B cell compartment after
anti-CD20 treatment these cells could represent potential
precursors for plasma cells. In this case, the precursor frequency
and the specificity of anti-GAD65 memory B cells of the patients
should be as different from the healthy donors as it was found for
anti-GAD65 serum antibodies. However, the comparison of the
frequency of circulating anti-GAD65 IgG
+ memory B cells and of
the epitope specificities between patient A and two healthy donors,
revealed only little if any differences. Therefore, it seems more
likely that the unchanged binding characteristics and only slightly
reduced serum titers of anti-GAD65 IgG autoantibodies were due
to the sustained activity of long-lived, rituximab-resistant plasma
cells. These autoreactive plasma cells are similar to plasma cells
that secrete antibodies to foreign antigens and pathogens like TT,
rotavirus and PnPs IgG. We cannot exclude however, that
switched memory cells were preserved in bone marrow, as it has
been reported by Rehnberg et al. [43] and Koelsch et al. [44].
In contrast to the high serum anti-GAD65 IgG titers and despite
of the unchanged inhibitory activity and conformational epitope
specificity of these antibodies, the analysis of human and mouse
brain sections revealed a clear reduction in the staining intensities
of GAD65-positive inhibitory synapses by IgG isolated after
rituximab treatment from twin A and twin B. Although these
differences may be caused by differences in thresholds, sensitivities
and displayed epitopes, a fraction of brain-specific autoreactive
IgG may be produced by short-lived plasma cells, which
continuously develop from rituximab-sensitive B cells. This is also
supported by our observation that IgG binding to linear GAD65
epitopes was reduced early (8 weeks) after anti-CD20 treatment.
Interestingly, the BCR repertoire that was found before
rituximab treatment showed a normal representation of VH
families for the IgM, G, and A isotypes. Therefore SPS seems to be
different from other autoimmune diseases, like pemphigus [8,45],
which is associated with skewed VH family usage. The clear
expansion of some IgG
+ and IgA
+ clones identified by the length of
Figure 4. Antibodies specific to GAD65 conformational epi-
topes are resistant to rituximab treatment. Binding of IgG from
twin A (A) and twin B (B) isolated at t=0 and at t=36 weeks to
radiolabeled GAD65 was analyzed in the presence of recombinant Fab
derived from GAD65-specific monoclonal antibodies. Grey bars
represent competitive binding of healthy control IgG. DPA, b96.11,
MICA-3, DPD, N-GAD65mAb, and b78 are monoclonal antibodies
specific for GAD65. The control Fab does not bind GAD65.
doi:10.1371/journal.pone.0010838.g004
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memory B cells after rituximab treatment. The newly emerging
cells may have survived the therapy if they were hidden in less
accessible tissues as it has been demonstrated for IgG
+ memory B
cells in rheumatoid arthritis [39,40,41,42].
While the total number of IgG memory B cells decreased, the
frequency of GAD65-specific IgG memory B cells increased 4-fold
after treatment. This relative increase in specific memory cells
could be caused by the specific survival of cells activated through
high affinity to GAD65 antigen, or by their location in niches
inaccessible to the treatment. Noteworthy, the frequency of
GAD65 memory cells in healthy controls was similar to that in
SPS patients before rituximab treatment, suggesting that B cell
tolerance to GAD65 seem not to be imposed during B cell
development at the stage of immature or transitional B cells but
during the formation of plasma cells in the germinal center
reaction. Furthermore, our data support the view [29] that the
antibody titer for certain antigens does not directly correlate with
the memory cell frequency.
Although rituximab penetrates the intact blood brain barrier, its
concentration in the cerebral spinal fluid (CSF) is 600–1000-fold
lower than in serum [46]. Therefore, the depletion of CSF B cells
may not be as efficient as for peripheral blood B cells [46,47] and
as a consequence, CSF may serve as reservoir for GAD65-specific
IgG memory B cells [47]. GAD65 antibodies were present both in
serum and in CSF prior to rituximab treatment, as reported
previously [21]. As we had no access to CSF samples after
treatment, the persistence of symptoms could also be explained
with intramedullar or intrathecal plasma or memory cells, which
were speared during anti-CD20 treatment and continued to
produce GAD65 antibodies.
Our study of two monozygotic twin brothers demonstrates for
the first time the repertoire and origins of autoreactive GAD65
specific B cells in SPS. Our data strongly argue in favor of the
hypothesis that long-lived plasma cells and rituximab-resistant
memory B cells are the main source of potentially pathogenic
GAD65-specific autoantibodies. Therefore the treatment of
autoantibody mediated autoimmune diseases with B cell depleting
Figure 5. Antibodies recognizing linear GA65 epitopes are sensitive to rituximab treatment. (A–C) Sera isolated from patients before (w0:
week 0) and after rituximab treatment (w36: week 36) and from 2 healthy donors (HD1, 2) were hybridized to peptide arrays covering the entire
GAD65 amino acid sequence. In graph A–C are represented the peptides specifically recognized by SPS patients sera. Filled and open symbols
represent samples from patients before and after B cells depletion, respectively. Significant differences in binding were determined by one-tailedT -
test (* ,0.1; ** ,0.05). For all peptides with the exception of 79–93 (PCSCSKVDNNYAFLH), p-values for the means between twin A/B week 0 and the
healthy donor sera were ,0.05. Data are representative of triplicate wells of 3 independent experiments. (D–H) On the same peptide array were
hybridized sera from twin A collected before and 8, 16, 36 weeks after rituximab treatment. Graphs represent relevant peptides. Data are
representative of triplicate wells of 2 independent experiments.
doi:10.1371/journal.pone.0010838.g005
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10838Figure 6. SPS IgG binding to brain structures is sensitive to rituximab treatment. (A) Sections were stained with a reference anti-GAD65
monoclonal antibody, column 1, and IgG of twin B, column 2. Column 3 represents the merged images and anti-calbindin staining (blue). Row a:
mouse cerebellum, Purkinje cell layer, t=0. Row b: mouse cerebellum, Purkinje cell layer, t=36 weeks after rituximab treatment. Row c: healthy
human cerebellum, Purkinje cell layer, t=0. Row d: healthy human cerebellum, Purkinje cell layer, t= 36 weeks after rituximab treatment. Solid
arrows mark GAD positive inhibitory synapses stained with IgG from twin B, thin arrows show presynaptic terminals staining only with the anti-
GAD65 monoclonal antibody. Slides were scanned at 102461024 pixel resolution with a Leica TCS NT confocal microscope, three channel recordings
were performed consecutively in Z-series with gaps of 250 nm between the optical slices. Parameters were held constant between recordings of
different samples. The stainings are representative for analyses performed with sections from 3 mouse and 3 healthy human samples with
immunoglobulin derived both from twin A and B. (B) Differential recognition of brain antigen before and after rituximab treatment. Serial consecutive
sections of three mouse brains were stained with IgG of twin B from t=0, twin B IgG week 36. Three fields of four different brain areas were analyzed
per mouse. Fluorescence signal intensities were examined by 10 linear measurements for a total of 600 mm per brain area and corrected for
background staining. For each the ratio between twin B IgG fluorescence intensity and anti-GAD65 monoclonal antibody fluorescence intensity was
calculated. Data represented are subtracted from the HD signals in the specific areas. Significant differences in staining were determined with
unpaired two-tailed T test (*** ,0.0001; ** ,0.001; * ,0.05).
doi:10.1371/journal.pone.0010838.g006
Humoral Memory in SPS
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plasma cells in protective niches.
Materials and Methods
Patients
Twin A and twin B are monozygotic twins affected by SPS, the
diagnosis of SPS was made in 2004 and 2002 respectively,
following Shaw’s criteria [48]. Both patients received rituximab in
two single injections of 1000 mg at two weeks of interval [21] in
accordance to the approval 78/2001 by the ethical committee of
the University Medical Center Freiburg. Written informed consent
for research and genetic analysis was obtained from all participants
to the study. Rituximab was well tolerated, but did not induce a
clear clinical benefit. GAD65 antibody titer was determined at
serial time point after B cells depletion, the titer was at lowest level
for both twins at week 36. Serum and isolated immunoglobulins of
both patients from week 36 after rituximab treatment were used in
all experiments, except otherwise indicated.
Genotyping, HLA typing and assessment of AIRE
polymorphisms
The genetic identity of the twins was verified by testing 9
microsatellite markers and HLA antigens (Table S1 a, b). The
probability for the twins being monozygotic is exceeding 99.96%
[49,50]. Both patients also had autoimmune thyroditis suggesting a
genetically based autoimmune response against endocrine glands
similar to autoimmune polyendocrine syndrome type I. We
therefore screened for mutations in coding and non-coding regions
of the autoimmune regulator (AIRE) gene but found only
polymorphisms previously described in autoimmune thyroditis
associated with systemic sclerosis [51] (Table S1c). Genomic DNA
was extracted from patients’ whole blood (Puregene DNA
Isolation Kit; Gentra Systems, USA). Genotyping PCR of 9
polymorphic microsatellite markers (Biomers, Germany and
Invitrogen, Germany) was performed at the recommended
conditions. PCR results were analyzed on an ABI 377 sequencer
(PE Applied Biosystems, Foster City, USA) with the COLLEC-
TION and ANALYSIS software packages (PE Applied Biosys-
tems). Allele sizes were determined with the help of GENOTY-
PER (PE Applied Biosystems). HLA typing was carried out by
PCR using standard methods. AIRE gene sequencing was
performed as described [51].
GAD65 specific antibody titers
96 well flat-bottomed NUNC Maxisorp microtiter plates
(Thermo Fischer Scientific, Denmark) were coated with recombi-
nant GAD65 protein (kindly provided by Dr. Kneusel, Diarect,
Germany), tetanus toxoid (kindly provided by Dr. E. Traggiai,
Gaslini Institute, Genova, Italy), or rotavirus A antigen (Institute
Virion, Ru ¨schlikon, Switzerland). Plates were blocked with PBS,
1% bovine serum albumin. Serial dilutions of sera were added for
each SPS patient and healthy controls (n=8). As detection
antibody, alkaline phosphatase conjugated goat anti-human IgG
(Jackson Immuno research laboratories, UK) was added. The
reaction was developed with Sigma-Aldrich 104 substrate
(p-nytriphenyl-phosphate) (Sigma, Germany).
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were stained for
15 minutes at 4uC with a mixture of the following antibodies at
optimal concentrations: CD27 FITC, CD24 FITC, IgD PE,
CD19 PE-Cy7, CD38 PerCp-Cy5.5 (all BD Biosciences, Ger-
many), Cy5-affinipure F (ab’)2 fragment donkey anti human IgM
(Jackson Immuno research laboratories, Suffolk, UK). Samples
were acquired with a BD FACSCanto II (BD Biosciences) and
further analyzed with FlowJo 7.2 Software (Tree Star Inc.,
Oregon, USA).
Limiting dilution
PBMC from patients and healthy controls were seeded at 100.
30. 10610
3 per well in 96 wells and stimulated with CpG (Apara
Biosciences, Germany) and rhIL-2 (Sigma, Germany). After 10
days, supernatants were tested by ELISA for anti-GAD65 IgG and
TT IgG. The frequency of GAD65 or TT specific memory cells is
expressed as number of positive clones/IgG
+ B cells at day 0 [28].
Spectratyping
Total RNA was prepared from PBMCs using the RNeasy kit
(Sigma, Deisenhofen, Germany) and cDNA following standard
protocols. PCR reactions were carried out by combining a primer
and a specific fluorophore-labeled probe for the constant region
CHm with one of eight primers covering the different VH1-7 genes
(European and US patent: Repertoire determination of a
lymphocyte B population, WO 2005/059176 A1; Pasteur
Institute, Paris, France [30]), using Taqman 7300 (Applied
Biosystems, Foster City, CA) and Applied Biosystems reagents.
PCR products underwent run-off reactions with a nested
fluorescent primer specific for the constant region gene. The
fluorescent products were analyzed on an ABI-PRISM 3730 DNA
analyzer. The size and intensity of each band were assessed with
Immunoscope software [52]. Amplification products correspond-
ing to the clonal expansions observed in P20 immunoscope profiles
were cloned, sequenced, and analyzed according to the procedure
described previously [30].
Purification of immunoglobulins
Patient and healthy donor serum IgG were affinity purified on
Protein G Sepharose (PGS) columns using standard methods
(protein G sepharose 4 fast flow, Amersham Pharmacia Biotech,
Sweden). Serum IgG was allowed to bind to PGS and was eluted
after washing with 0.1 M glycine buffer pH 3. Eluted fractions
were immediately neutralized by addition of 1 M Tris-HCl
pH 8.8. Isolated IgG were dialyzed against PBS overnight at 4uC.
GAD65 enzyme activity assay
GAD65 enzyme activity was measured by the
14CO2-trapping
method described previously [53]. Recombinant human GAD65
(donation by Amgen, Seattle, WA) (100 ng) was incubated with
reaction buffer (50 mM K2HPO4, 0.03 mM PLP, 0.1 mM DTT,
pH 6.8) for 1 hour at room temperature with or without the
indicated amounts of isolated IgG. The enzymatic reaction was
initiated by the addition of 0.56 mM L-glutamate and 0.018 mCi
14C-glutamate (Perkin Elmer, Boston MA, USA) and allowed to
continue for 2 hours at 37uC with gentle agitation. During
incubation, released
14CO2 was captured on filter paper (Kontes,
Vineland, NJ) soaked in 50 ml 1 M NaOH. After the incubation,
the absorbed radioactivity was determined in a Beckman
scintillation counter. The results are presented as: % residual
activity = cpm in the presence of IgG/cpm in the absence of
IgG6100.
rFab used in this study
Monoclonal antibodies b96.11 and b78 were derived from a
patient with autoimmune polyendocrine syndrome – type 2 [54],
and recognized conformational epitopes formed by the 3D
structure of amino acid residues 308–365 and 451–585,
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recognized linear epitopes representing amino acid residues 4–22
[56]. DPA and DPD were isolated from a type 1 diabetes
patient[57] and recognized epitopes that mapped between amino
acid residues 483–585 and 96–173, respectively [58,59]. MICA-3
was isolated from a type 1 diabetes patient[60] and recognized
epitopes of amino acid region 451–585 [59,61]. All mAbs
recognized GAD65 in its native conformation and do not bind
GAD67. In the competitive radioligand-binding assay, the rFab
were added at the optimal concentration (0.7–1 mg/ml) as
determined in competition assays using the intact mAb as a
competitor.
Epitope mapping by Fab2 antibody competition
Inhibition of human IgG binding to GAD65 by rFab was tested
in a competitive radioligand-binding assay[34]. The cutoff for
specific competition was determined as .10% by using as a
negative control rFab D1.3 (a kind gift from Dr. J. Foote,
Arrowsmith Technologies, Seattle) specific for the irrelevant
target, hen-egg lysozyme. Binding of SPS IgG to GAD65 in the
presence of rFab was expressed as follows: cpm in the presence of
rFab/cpm in the absence of rFab6100.
Linear epitope mapping using peptide microarrays
Replitope
TM high density microarrays were provided by JPT
Peptide Technologies GmbH, (Berlin, Germany) [62]. The
peptides on the arrays represent a linear scan of 15mer peptides
derived from human GAD65 (NCBI refseq protein accession
NP_000809) that overlap by 9 amino acids, with human IgG
spotted as control. Staining was carried out as described [62]. Sera
from twin A and B, and 2 healthy controls were tested, as negative
control we stained with secondary reagent only. Fluorescent
signals were detected with Agilent G250B scanner, analyzed with
GenePix Pro (Molecular Devices; Ismaning, Germany). The
median intensity of each spot was corrected by subtraction with
the median local background. The heatmap was generated using
CIMminer (http://discover.nci.nih.gov/cimminer/).
Histology
Tissue processing and immunolabelling. Brain samples
from C57 BL/6 mice were isolated from anesthetized and
perfused animals[63]. Immersion fixation was performed
overnight in the same fixative. Human brain samples (covered
by the approval number 256/06 of the ethical committee of the
University Medical Center Freiburg) were obtained from an
18 hours postmortem patient who did not suffer from a central
nervous disease and material was immersion fixed in formalin for
two weeks. Tissue samples of both origins were paraffin-
embedded, cut to 3–5 mm sections, heated at 80uC for 1 hour,
dewaxed with xylene, rehydrated and treated in citrate buffer,
pH 6.0, for 4 min in a pressure cooker to demask antigenic sites.
Sections were rinsed in PBS, mounted in Shandon coverplate trays
(Thermo Electron Corp., Pittsburgh, PA), blocked with 1% BSA in
PBS/0.1% Triton X-100 for 30 min and incubated with primary
antibodies diluted in 1% blocking buffer overnight at room
temperature. Rinsed samples were incubated with secondary
antibodies for 4 hours. Tissue and lipofuscin autofluorescence was
quenched by equilibrating the specimens in a 50% PBS/ethanol
mixture for 2 min followed by Sudan B (0.1%) dissolved in 70%
ethanol [64]. After rinsing in 50% PBS/ethanol and PBS the
sections were covered with anti-fading agent (Calbiochem, La
Jolla, CA) and stored overnight at 4uC before observation. Patient
and healthy donor IgG were used at comparable concentration for
staining, working concentrations for primary and secondary
antibodies (reference anti-GAD65 monoclonal antibody: N-
GAD65mAb[56], anti-calbindin, Swant) were determined
empirically to ensure optimal/signal background staining.
Immunocytochemistry and image analysis. Immun-
ofluorescences were scanned at 102461024 pixel resolution with
a confocal microscope (Leica, Germany). Three or two channel
recordings were performed consecutively in Z-series with gaps of
250 nm between the optical slices. Confocal stacks of Z-planes
were stored as TIF-files and processed in the Imaris 4.2 software
(Bitplane AG, Switzerland). Compiling was carried out by means
of the Adobe Creative Suite 2 software.
For quantitative estimation of patient-IgG and anti GAD-IgG
immunoreactivity the corresponding fluorescence signals of
synapses was measured by recording the pixel intensities along a
line spanning the synapse in question. Consecutive mouse brain
sections of three C57/BL6 mice were analyzed resulting in a total
of 600 mm linear scans for each of 4 brain areas analyzed per
mouse.
Supporting Information
Table S1 Genetic analysis and AIRE polymorphisms. Monozy-
gosity was analyzed using 9 microsatellite markers (a) and HLA
typing (b). Polymorphisms in exons 6, 10, 14, and introns 7 and 9
are shown in (b).
Found at: doi:10.1371/journal.pone.0010838.s001 (0.06 MB
DOC)
Figure S1 Antibodies recognizing linear GA65 epitopes are
sensitive to rituximab treatment. Sera isolated from patients before
(w0: week 0) and after rituximab treatment (w36: week 36) and
from 2 healthy donors (HD1, 2) were hybridized to peptide arrays
covering the entire GAD65 amino acid sequence. The heatmap
represents the average background corrected signal intensities of
triplicates. The columns show independent experiments, signals
from binding of secondary antibodies to human IgG (IgG human)
were used as internal control.
Found at: doi:10.1371/journal.pone.0010838.s002 (6.32 MB TIF)
Figure S2 Specificity of memory B cells for linear GAD65
epitopes. The heatmap represents signal intensities derived from
GAD65 peptide array assays incubated with 1:2 diluted superna-
tants of GAD65 specific IgG
+ memory B cells clones isolated from
a healthy donor (HD) and twin A by limiting dilution. B cells
clones were isolated from twin A at t=0 as well as t=36 (week 36).
As references, 1:100 diluted sera from twin A week 0 and 36 (0 and
36 respectively) as well as HD were assayed in parallel. Each
column corresponds to one sample, i.e., one B cell supernatant or
serum, each row to one of the 96 overlapping GAD65 linear
peptides, represented progressively from the N-terminal to the C-
terminal of GAD65 protein. Black arrows indicate peptides bound
both by twin A supernatants of limiting dilution culture and serum,
red arrows are peptide bound by HD supernatant of limiting
dilution culture, blue arrows indicate peptides bound only by twin
A supernatants, the green arrow indicate peptide bound only by
twin A supernatant of culture and serum from week 36. The
heatmap is representative of 2 experiments performed.
Found at: doi:10.1371/journal.pone.0010838.s003 (5.23 MB TIF)
Figure S3 Staining of brain cryosections with IgG from healthy
controls. Immunofluorescence controls were performed with
reference antibody anti-GAD65 (column 1) and with IgG isolated
from healthy donor (HD) (column 2) on mouse (row a and b) and
human cerebellum (row c and d). In column 3 the red and green
channels were merged with the blue channel indicating calbindin
immunofluorescence of purkinje cells. Control sections by
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fluorochrome labeled antibodies only (rows b and d). The stainings
are representative for analyses performed with sections from 3
mouse and 3 human samples.
Found at: doi:10.1371/journal.pone.0010838.s004 (7.12 MB TIF)
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